血清miR-145及MMP-2水平预测三阴性乳腺癌新辅助化疗后病理完全缓解的价值  

Value of serum miR-145 and MMP-2 levels in predicting pathological complete response after neoadjuvant chemotherapy for triple-negative breast cancer

作　　者：谷振芳[1] 胡东玉[1] 徐保彬[1] 李伟[1] 张春梅[1] Gu Zhenfang;Hu Dongyu;Xu Baobin;Li Wei;Zhang Chunmei(Oncology Department,Jining Medical College Affiliated Hospital,Jining 272100,China)

机构地区：[1]济宁医学院附属医院肿瘤科,济宁272100

出　　处：《中华内分泌外科杂志（中英文）》2024年第3期399-403,共5页Chinese Journal of Endocrine Surgery

基　　金：济宁市重点研发计划(软科学)项目 (2022JNZC039)。

摘　　要：目的探讨血清miR-145及基质金属蛋白酶-2(matrixmetallo proteinase-2,MMP-2)水平预测三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗后病理完全缓解(pathologic complete response,pCR)的价值。方法前瞻性纳入2022年1月至2023年12月于济宁医学院附属医院就诊并进行新辅助化疗的125例TNBC患者作为研究对象,并纳入与观察组年龄相匹配的130例同期在本院进行体检的健康人作为健康对照组。采用实时荧光定量聚合酶链反应对所有研究对象血清miR-145水平进行检测。采用酶联免疫吸附实验法测定患者血清MMP-2的水平。新辅助化疗后,根据Miller-Payne(MP)分级标准对患者进行疗效评估,分为pCR组和非pCR组。结果TNBC患者血清miR-145水平为1.49±0.27,显著低于健康对照组的2.79±0.49,差异有统计学意义(t=20.33,P<0.001);TNBC患者血清MMP-2水平为(153.07±38.36)ng/mL,显著高于健康对照组的(84.38±12.63)ng/mL,差异有统计学意义(t=26.13,P<0.001)。新辅助化疗后非pCR患者的治疗前血清miR-145水平为1.36±0.21,显著低于pCR组的(1.74±0.20),差异有统计学意义(t=9.93,P<0.001);新辅助化疗后非pCR患者的治疗前血清MMP-2水平为(169.57±30.45)ng/mL,显著高于pCR组的(121.61±31.79)ng/mL,差异有统计学意义(t=8.24,P<0.001)。Pearson相关性分析结果显示,TNBC患者治疗前血清miR-145与MMP-2水平呈显著负相关关系(r=-0.47,P<0.001)。ROC曲线分析结果显示,治疗前血清miR-145、MMP-2水平预测TNBC新辅助化疗后pCR的灵敏度和特异度分别为82.9%和74.4%、45.1%和99.8%,两者联合预测TNBC新辅助化疗后pCR的灵敏度和特异度分别为84.1%和88.4%。结论血清miR-145及MMP-2水平与TNBC患者新辅助化疗后的疗效有关,且两者联合应用有一定预测价值。Objective To investigate the value of serum miR-145 and matrixmetallo proteinase-2(MMP-2)levels in predicting pathologic complete response(pCR)after neoadjuvant chemotherapy in triple-negative breast cancer.Methods 125 patients with triple-negative breast cancer who received neoadjuvant chemotherapy in the Hospital from Jan.2022 to Dec.2023 were prospectively included as the study objects,and 130 healthy people matching the age of the case group who underwent physical examination in our hospital during the same period were included as the healthy control group.Real-time fluorescence quantitative polymerase chain reaction was used to detect the serum miR-145 level of all subjects.Serum MMP-2 levels were determined by enzyme-linked immunosorbent assay(ELISA).After neoadjuvant chemotherapy,patients were evaluated according to Miller-Payne(MP)grading criteria and divided into pCR group and non-PCR group.Results The serum miR-145 level in patients with tertiary breast cancer was 1.49±0.27,which was significantly lower than that in healthy control group(2.79±0.49),with statistical significance(t=20.33,P<0.001).The serum MMP-2 level in triple negative breast cancer patients was(153.07±38.36)ng/mL,which was significantly higher than that in healthy control group(84.38±12.63)ng/mL,and the difference was statistically significant(t=26.13,P<0.001).After neoadjuvant chemotherapy,the serum miR-145 level in non-PCR patients before treatment was 1.36±0.21,which was significantly lower than that in pCR group(1.74±0.20),with statistical significance(t=9.93,P<0.001).After neoadjuvant chemotherapy,the serum MMP-2 level in non-PCR patients before treatment was(169.57±30.45)ng/mL,which was significantly higher than that in pCR group(121.61±31.79)ng/mL,and the difference was statistically significant(t=8.24,P<0.001).Pearson correlation analysis showed that there was a significant negative correlation between serum miR-145 and MMP-2 levels in patients with triple-negative breast cancer before treatment(r=-0.47,P<0.001).ROC curv

关 键 词：三阴性乳腺癌 新辅助化疗 病理完全缓解 MIR-145 基质金属蛋白酶-2 

分 类 号：R737.9[医药卫生—肿瘤]